Riluzole neuroprotection in a parkinson’s disease model involves suppression of reactive astrocytosis but not GLT-1 regulation.
KeywordRiluzole, EAAT2, GLT-1, Neuroprotection, Parkinson’s Disease, GFAP, Glial cell, 6-hydroxydopamine
Rights© 2012 Carbone et al. Published Open Access by BioMed Central. Reproduced in accordance with the publisher's self-archiving policy.